Previous close | 2.1400 |
Open | 2.1000 |
Bid | 2.0300 x 1100 |
Ask | 2.3700 x 1000 |
Day's range | 2.0500 - 2.1700 |
52-week range | 1.3400 - 19.5000 |
Volume | |
Avg. volume | 66,616 |
Market cap | 27.044M |
Beta (5Y monthly) | 1.74 |
PE ratio (TTM) | N/A |
EPS (TTM) | -14.8540 |
Earnings date | 13 Mar 2023 - 17 Mar 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.25 |
DEERFIELD, Ill., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (Nasdaq: SRGA), a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced a key milestone for its recently introduced posterior fixation platform – the Cortera™ Spinal Fixation System. Surgalign received FDA 510(k) in August 2022 and Cortera and was introduced in a limited market release shortly thereafter. In a little over three months, the
Richmond, VA medical facility is fourth to clinically use HOLO Portal, the world’s first artificial intelligence (AI)-driven, augmented reality (AR) guidance system for spine surgeryDEERFIELD, Ill., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced additional commercialization of its HOLO Portal surgical guidance system. The Company is
DEERFIELD, Ill., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (Nasdaq: SRGA), a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced that the closing of its previously announced registered direct offering priced at the market under Nasdaq rules of 6,000,000 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and Series A warrants to purchase up to 6,000,000 shares of common